Abstract
Epstein–Barr virus (EBV) is a B-lymphocytes herpes virus and can transform B lymphocytes to malignant tumor cells if infected. Nasopharyngeal carcinoma (NPC) is strongly associated with EBV. Circulating EBV DNA in plasma has been recognized as an important biomarker of NPC. Much work has been done to validate the ability of circulating EBV DNA for screening, diagnosis, risk stratification, monitoring, and predicting prognosis. This chapter reviews the clinical progress of circulating cell-free EBV DNA in NPC.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Chen YP, Chan ATC, Le QT et al (2019) Nasopharyngeal carcinoma. Lancet 394(10192):64–80
Chua MLK, Wee JTS, Hui EP et al (2016) Nasopharyngeal carcinoma. Lancet 387(10022):1012–1024
Guo R, Tang LL, Mao YP et al (2019) Proposed modifications and incorporation of plasma Epstein-Barr virus DNA improve the TNM staging system for Epstein-Barr virus-related nasopharyngeal carcinoma. Cancer 125(1):79–89
Lin JC, Wang WY, Chen KY et al (2004) Quantification of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma. N Engl J Med 350(24):2461–2470
Lo YM, Chan LY, Lo KW et al (1999) Quantitative analysis of cell-free Epstein-Barr virus DNA in plasma of patients with nasopharyngeal carcinoma. Cancer Res 59(6):1188–1191
Qu H, Huang Y, Zhao S et al (2020) Prognostic value of Epstein-Barr virus DNA level for nasopharyngeal carcinoma: a meta-analysis of 8128 cases. Eur Arch Otorhinolaryngol 277(1):9–18
Lam WKJ, Chan KCA, Lo YMD (2019) Plasma Epstein-Barr virus DNA as an archetypal circulating tumour DNA marker. J Pathol 247(5):641–649
Chan KCA, Woo JKS, King A et al (2017) Analysis of plasma Epstein-Barr virus DNA to screen for nasopharyngeal cancer. N Engl J Med 377(6):513–522
Lee VH, Kwong DL, Leung TW et al (2019) The addition of pretreatment plasma Epstein-Barr virus DNA into the eighth edition of nasopharyngeal cancer TNM stage classification. Int J Cancer 144(7):1713–1722
Shotelersuk K, Khorprasert C, Sakdikul S et al (2000) Epstein-Barr virus DNA in serum/plasma as a tumor marker for nasopharyngeal cancer. Clin Cancer Res 6(3):1046–1051
To EW, Chan KC, Leung SF et al (2003) Rapid clearance of plasma Epstein-Barr virus DNA after surgical treatment of nasopharyngeal carcinoma. Clin Cancer Res 9(9):3254–3259
Lo YM, Leung SF, Chan LY et al (2000) Kinetics of plasma Epstein-Barr virus DNA during radiation therapy for nasopharyngeal carcinoma. Cancer Res 60(9):2351–2355
Yip TT, Ngan RK, Fong AH et al (2014) Application of circulating plasma/serum EBV DNA in the clinical management of nasopharyngeal carcinoma. Oral Oncol 50(6):527–538
Chan AT, Lo YM, Zee B et al (2002) Plasma Epstein-Barr virus DNA and residual disease after radiotherapy for undifferentiated nasopharyngeal carcinoma. J Natl Cancer Inst 94(21):1614–1619
Zhang Y, Tang LL, Li YQ et al (2019) Spontaneous remission of residual post-therapy plasma Epstein-Barr virus DNA and its prognostic implication in nasopharyngeal carcinoma: a large-scale, big-data intelligence platform-based analysis. Int J Cancer 144(9):2313–2319
Makitie AA, Reis PP, Irish J et al (2004) Correlation of Epstein-Barr virus DNA in cell-free plasma, functional imaging and clinical course in locally advanced nasopharyngeal cancer: a pilot study. Head Neck 26(9):815–822
Peng H, Li Z, Long Y et al (2019) Clinical value of a plasma Epstein-Barr virus DNA assay in the diagnosis of recurrent or metastatic nasopharyngeal carcinoma: a meta-analysis. Biosci Rep:39(9)
Ng RH, Ngan R, Wei WI et al (2014) Trans-oral brush biopsies and quantitative PCR for EBV DNA detection and screening of nasopharyngeal carcinoma. Otolaryngol Head Neck Surg 150(4):602–609
Lam JW, Chan JY, Ho WK et al (2016) Use of transoral nasopharyngeal brush biopsy for Epstein-Barr virus DNA detection of local recurrence of nasopharyngeal carcinoma after radiotherapy. Head Neck 38(Suppl 1):E1301–E1304
Leung SF, Zee B, Ma BB et al (2006) Plasma Epstein-Barr viral deoxyribonucleic acid quantitation complements tumor-node-metastasis staging prognostication in nasopharyngeal carcinoma. J Clin Oncol 24(34):5414–5418
Chen WH, Tang LQ, Guo SS et al (2016) Prognostic value of plasma Epstein-Barr virus DNA for local and regionally advanced nasopharyngeal carcinoma treated with cisplatin-based concurrent chemoradiotherapy in intensity-modulated radiotherapy era. Medicine (Baltimore) 95(5):e2642
You R, Liu YP, Lin M et al (2019) Relationship of circulating tumor cells and Epstein-Barr virus DNA to progression-free survival and overall survival in metastatic nasopharyngeal carcinoma patients. Int J Cancer 145(10):2873–2883
Liu LT, Tang LQ, Chen QY et al (2015) The prognostic value of plasma Epstein-Barr viral DNA and tumor response to neoadjuvant chemotherapy in advanced-stage nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 93(4):862–869
Leung SF, Chan KC, Ma BB et al (2014) Plasma Epstein-Barr viral DNA load at midpoint of radiotherapy course predicts outcome in advanced-stage nasopharyngeal carcinoma. Ann Oncol 25(6):1204–1208
Zhang J, Shu C, Song Y et al (2016) Epstein-Barr virus DNA level as a novel prognostic factor in nasopharyngeal carcinoma: a meta-analysis. Medicine (Baltimore) 95(40):e5130
Wang WY, Twu CW, Lin WY et al (2011) Plasma Epstein-Barr virus DNA screening followed by (1)(8)F-fluoro-2-deoxy-D-glucose positron emission tomography in detecting posttreatment failures of nasopharyngeal carcinoma. Cancer 117(19):4452–4459
Twu CW, Wang WY, Chen CC et al (2014) Metronomic adjuvant chemotherapy improves treatment outcome in nasopharyngeal carcinoma patients with postradiation persistently detectable plasma Epstein-Barr virus deoxyribonucleic acid. Int J Radiat Oncol Biol Phys 89(1):21–29
Chan ATC, Hui EP, Ngan RKC et al (2018) Analysis of plasma Epstein-Barr virus DNA in nasopharyngeal cancer after chemoradiation to identify high-risk patients for adjuvant chemotherapy: a randomized controlled trial. J Clin Oncol 36(31):3091–3100
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2020 Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
Xue, F., He, X. (2020). Epstein–Barr Virus DNA in Nasopharyngeal Carcinoma: A Brief Review. In: Huang, T. (eds) Precision Medicine. Methods in Molecular Biology, vol 2204. Humana, New York, NY. https://doi.org/10.1007/978-1-0716-0904-0_9
Download citation
DOI: https://doi.org/10.1007/978-1-0716-0904-0_9
Published:
Publisher Name: Humana, New York, NY
Print ISBN: 978-1-0716-0903-3
Online ISBN: 978-1-0716-0904-0
eBook Packages: Springer Protocols